Transdermal nortriptyline hydrocloride patch formulated within a chitosan matrix intended to be used for smoking cessation

Pharmaceutical Development and Technology

Volumn 16, Issue 2, 2011, Pages 162-169

  Escobar Chávez, José Juan ^a,b   Merino, Virginia ^a   Díez Sales, Octavio ^a   Nácher Alonso, Amparo ^a   Ganem Quintanar, Adriana ^b   Herráez, Marina ^a   Merino Sanjuán, Matilde ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

iontophoresis; PF 127; Nortriptyline hydrochloride; passive diffusion; skin; smoking cessation; transdermal patch

Indexed keywords

CHITOSAN; LAURYL ALCOHOL; NORTRIPTYLINE;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG PENETRATION; FLOW KINETICS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IONTOPHORESIS; MICROSCOPY; PRIORITY JOURNAL; ROOM TEMPERATURE; SMOKING CESSATION;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHITOSAN; FEMALE; HUMANS; IONTOPHORESIS; MIDDLE AGED; NORTRIPTYLINE; SKIN; SMOKING CESSATION; TRANSDERMAL PATCH;

EID: 79953038869     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450903584902     Document Type: Article

References (45)

1. Accessed from the website: http://www.cdc.gov/Tobacco/sgr/sgr-1964/sgr64. htm
2. Accessed from the website: http://www.who.int/tobacco/en
3. Accessed from the website: http://www.fctc.org
4. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: Combination of national statistics with two case-control studies. BMJ 2000;321:323-329. (Pubitemid 30496873)
5. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. Te efects of a smoking cessation intervention on 14.5-year mortality: A randomized clinical trial. Ann Intern Med 2005;142:233-239. (Pubitemid 40216240)
6. Maes HH, Sullivan PF, Bulik CM, Neale MC, Prescott CA, et al. A twin study of genetic and environmental infuences on tobacco initiation, regular tobacco use and nicotine dependence. Psychol Med 2004;34:1251-1261. (Pubitemid 39517155)
7. Perry CL, Eriksen MP, Giovino G. Tobacco use: A paediatric epi-demic Tob Control 1994;3:97-98.
8. Peto R, Lopez AD, Boreham J. Mortality from smoking in developed countries 1950-2000. Oxford, UK: Oxford University Press; 2004.
9. US Department of Health and Human Services. Te Health Benefts of Smoking Cessation. Washington, DC, US: Government Printing Ofce, 1990.
10. US Department of Health and Human Services. Te health con-sequences of smoking: Nicotine addiction. Washington, DC, US: Government Printing Ofce, 1988
11. Royal College of Physicians. Nicotine addiction in Britain: A report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians; 2000.
12. Foulds J, Burke M, Steinberg M. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004;9:39-53. (Pubitemid 38715577)
13. Benowitz NL. Drug therapy. Pharmacologic aspects of ciga-rette smoking and nicotine addiction. N Engl J Med 1988; 319:1318-1330. (Pubitemid 19003394)
14. Scherer G. Smoking behavior and compensation: A review of the literature. Psychopharmacology 1999;145:1-20. (Pubitemid 29339758)
15. Hall SM, Reus VI, Munoz RF, Sees KL, Humfeet G, et al. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998;55:683-690. (Pubitemid 28364383)
16. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 1998;158:2035-2039. (Pubitemid 28465629)
17. da Costa CL, Younes RN, Lourenco MT. Stopping smoking: A pro-spective, randomized, double-blind study comparing nortriptyl-ine to placebo. Chest 2002;122:403-408. (Pubitemid 35002113)
18. Escobar-Chávez JJ, Merino V, López-Cervantes Miriam, Rodríguez-Cruz IM, Quintanar-Guerrero D, Ganem-Quintanar A. Te use of iontophoresis in the administration of nicotine and new non-nicotine drugs through the skin for smoking cessation. Current Drug Discovery Technologies 2009;6(3):171-185.
19. Hall SM, Humfeet GL, Reus VI Munoz RF, Hartz DT, Maude-Grifn R. Psychological intervention and antidepres-sant treatment in smoking cessation. Arch Gen Psychiatry 2002;59:930-936.
20. Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking ces-sation: A review. Nicotine Tob Res 2005; 7:491-499.
21. http://www.emea.europa.eu/pdfs/human/qwp/060996en.pdf
22. Howes D, Guy R, Hadgraft J, Heylings J, Hoeck U, Kemper F, Maibach H, Marty JP, Merk H, Parra J, Rekkas D, Rondelli I, Schaefer H, Tauber U, Verbiese N. Methods for assessing percu-taneous absorption. Te report and recommendations of ECVAM workshop 13. ATLA 1996;24:81-106.
23. Femenía-Font A, Balaguer-Fernández C, Merino V, López-Castellano. A. iontophoretic transdermal delivery of sumatriptan: Efect of current density and ionic strength. J Pharm Sci 2005;94(10):2183-2186. (Pubitemid 41665279)
24. Ghahramani P, Lennard MS. Quantitative analysis of amitryp-tiline and nortriptyline in human plasma and liver microsomal preparations by high performance liquid chromatography. J Chromatogr B Biomed Appl 1996;685(2):307-313. (Pubitemid 26382412)
25. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: Bioavailability, bioequiv-alence and pharmacokinetic studies. J Pharm Sci 1992; 81(3):309-312.
26. Merino V, Micó-Albiñana T, Nácher A, Díez-Sales O, Herráez M, Merino-Sanjuán M. Enhancement of nortriptyline penetration through human epidermis: Infuence of chemical enhancers and iontophoresis. J Pharm Pharmacol 2008;60(4):415-420. (Pubitemid 351500551)
27. Ammar HO, Salama HA, El-Nahhas SA, Elmotasem H. Design and evaluation of chitosan flms for transdermal delivery of glimepiride. Curr Drug Deliv 2008;5(4):290-298.
28. Nair V, Panchangula R. Poloxamer gel as vehicle for transder-mal iontophoretic delivery of arginine vasopressin: Evaluation of in vivo performance in rats. Pharmacol Res 2003;47(6): 555-562. (Pubitemid 36542936)
29. Oechsner M, Keipert S. Polyacrylic acid/polyvinylpyrrolidone bipolymeric systems. I. Rheological and mucoadhesive proper-ties of formulations potentially useful for the treatment of dry-eye-syndrome. Eur J Pharm Biopharm 1999;47(2):113-118. (Pubitemid 29185113)
30. Diez-Sales O, Dolz M, Hernández MJ, Casanovas A., Herraez M. Acyclovir delivery matrices basedon poly(ethylene glicol)/chitosan semi-interpenetrating networks. J Pharm Sci 2007;96(6):1653-1657. (Pubitemid 46953779)
31. Koller C, Buri P. Propriété e intérêt pharmaceutique des gels thermoréversibles a base de poloxamers et poloxamines. STP Pharmaceutics 1987;3(2):115-124. (Pubitemid 17047482)
32. Miyazaki S, Takeuchi S, Yokouchi C, Takada M. PluronicF-127 gels as vehicles for topical administration of anticancer agents. Chem Pharm Bull 1984;32(10):4205-4208. (Pubitemid 15208373)
33. Gilbert JC, Hadgraft J, Bye A, Brookes L. Drug release from Pluronic F-127 gels. Int J Pharm 1986;32:223-228. (Pubitemid 16015303)
34. DiBiase M, Rhodes C Formulation and evaluation of epider-mal growth factor in Pluronic-127 gel. Drug Develop Ind Pharm 1996;22(8):823-831. (Pubitemid 26272588)
35. Pillai O, Pachagnula R. Transdermal delivery of insulin from poloxamer gel: Ex vivo and in vivo skin permeation studies in rat using iontophoresis and chemical enhancers. J Control Release 2003;89(1):127-140. (Pubitemid 36412117)
36. Escobar-Chávez JJ, Quintanar-Guerrero D, Ganem-Quintanar A. In vivo skin permeation of sodium naproxen formulated in PF-127 gels: Efect of Azone® and Transcutol®. Drug Develop Ind Pharm 2005;31:447-454. (Pubitemid 41289157)
37. Escobar-Chávez JJ, López-Cervantes M, Naïk A, Kalia YN, Quintanar-Guerrero D, Ganem-Quintanar A. Applications of the thermoreversible Pluronic F-127 gels in pharma-ceutical formulations. J Pharm Pharmaceut Sci 2006;9(3): 339-358. (Pubitemid 46655458)
38. Escobar-Chávez JJ, Merino-Sanjuán V, López-Cervantes M. Te tape-stripping technique as a method for drug quantifcation in skin. J Pharm Pharmaceut Sci 2008;11(1):104-130.
39. Escobar-Chávez JJ, Melgoza-Contreras LM, López-Cervantes M, Quintanar-Guerrero D, Ganem-Quintanar A. Te tape stripping technique as a valuable tool for evaluating topical applied com-pounds. In: Caldwell GW, Atta-ur-Rahman FRS, Yan Z, et al., editors. Frontiers in Drug Design & Discovery. Te Netherlands: Bentham Science Publishers; 2009;(4):189-227.
40. Melero A, Garrigues TM, Almudever P, Martín Villodre A, Lehr CM, Schäfer U. Nortriptyline hydrochloride skin absorption: Development of a transdermal match. Eur J Pharm Biopharm 2008;69:588-596.
41. Merlé Y Mentré F. Optimal sampling times for Bayesian estima-tion of the pharmacokinetic parameters of nortriptyline dur-ing therapeutic drug monitoring. J Pharmacokinet Biopharm 1999;27(1):85-101. (Pubitemid 29382289)
42. Mooney ME, Reus VI, Gorecki J, Hall SM, Humfeet GL, Muñoz RF, Delucchi K. Terapeutic drug monitoring of nortriptyline in smoking cessation: A multistudy analysis. Clin Pharmacol Ter 2008;83(3):436-442. (Pubitemid 351272631)
43. Varghese E, Khar RK. Enhanced skin permeation of diclofenac by iontophoresis: In vitro and in vivo studies. J Control Rel 1996;38:21-27. (Pubitemid 26027175)
44. Schmidt JB, Binder M, Maicheiner W. New treatment of atrophic acne scars by iontophoresis with estriol and tretinoin. Int J Dermatol 1995;34:53-57.
45. Siegel SJ, O'Neill C, Dube L, Kaldeway P, Morris R, Jackson D, Sebree T. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res 2007;24(10): 1919-1926. (Pubitemid 47389248)